Scholar Rock Holding Corp (NASDAQ:SRRK) – Stock analysts at Jefferies Financial Group boosted their Q2 2019 earnings per share (EPS) estimates for shares of Scholar Rock in a report released on Tuesday, May 14th. Jefferies Financial Group analyst M. Yee now expects that the company will post earnings per share of ($0.42) for the quarter, up from their prior forecast of ($0.66). Jefferies Financial Group also issued estimates for Scholar Rock’s Q3 2019 earnings at ($0.49) EPS, Q4 2019 earnings at ($0.58) EPS, FY2019 earnings at ($1.91) EPS and FY2020 earnings at ($2.94) EPS.
Other equities analysts have also recently issued reports about the company. Wedbush reissued an “outperform” rating and set a $27.00 target price on shares of Scholar Rock in a research note on Wednesday. Zacks Investment Research raised Scholar Rock from a “sell” rating to a “hold” rating in a research note on Thursday, May 9th. ValuEngine raised Scholar Rock from a “hold” rating to a “buy” rating in a research note on Tuesday, May 7th. Finally, Cowen reissued a “buy” rating on shares of Scholar Rock in a research note on Wednesday, February 27th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Scholar Rock presently has a consensus rating of “Buy” and a consensus price target of $27.25.
Scholar Rock (NASDAQ:SRRK) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.42) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.08. The company had revenue of $3.11 million during the quarter, compared to analysts’ expectations of $5.05 million.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Federated Investors Inc. PA increased its stake in shares of Scholar Rock by 26.5% during the first quarter. Federated Investors Inc. PA now owns 3,577 shares of the company’s stock valued at $67,000 after buying an additional 750 shares during the period. BlackRock Inc. increased its stake in shares of Scholar Rock by 0.4% during the fourth quarter. BlackRock Inc. now owns 369,810 shares of the company’s stock valued at $8,494,000 after buying an additional 1,447 shares during the period. Citigroup Inc. increased its stake in shares of Scholar Rock by 122.8% during the first quarter. Citigroup Inc. now owns 3,970 shares of the company’s stock valued at $74,000 after buying an additional 2,188 shares during the period. BNP Paribas Arbitrage SA purchased a new position in shares of Scholar Rock during the first quarter valued at approximately $59,000. Finally, Northern Trust Corp grew its stake in Scholar Rock by 5.7% in the fourth quarter. Northern Trust Corp now owns 69,825 shares of the company’s stock worth $1,604,000 after purchasing an additional 3,791 shares during the period. 51.64% of the stock is currently owned by hedge funds and other institutional investors.
About Scholar Rock
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.
Recommended Story: How is an ETF different from a mutual fund?
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.